ABBV-903 is a different anti-Covid drug that has only been tested in a 24 patient phase I safety trial. It has been listed as a protease inhibitor. If ABBV is showing interest in protease inhibitors, then EDP-235 remains a potential partner.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.